Dalbavancin Side Effects

Medically reviewed by Drugs.com. Last updated on Jul 9, 2024.

Applies to dalbavancin: intravenous powder for solution.

Precautions

It is very important that your doctor check your or your child's progress closely while receiving this medicine to make sure it is working properly. Blood tests may be needed to check for unwanted effects.

This medicine may cause serious allergic reactions, including skin reactions and anaphylaxis, which can be life-threatening and require immediate medical attention. Tell your doctor right away if you have a rash, itching, trouble breathing, trouble swallowing, or any swelling of your hands, face, or mouth while you are using this medicine.

This medicine may cause infusion-related reactions, which can be life-threatening and require immediate medical attention. Tell your doctor right away if you have a cough, difficulty with swallowing, dizziness, fast heartbeat, trouble breathing, swelling in your face or hands, fever, chills, itching or hives, or feeling of warmth or redness on your upper body while you are receiving this medicine.

Check with your doctor right away if you have pain or tenderness in the upper stomach, pale stools, dark urine, loss of appetite, nausea, vomiting, or yellow eyes or skin. These could be symptoms of a serious liver problem.

This medicine may cause diarrhea, and in some cases it can be severe. It may also occur 2 months or more after you stop using this medicine. Do not take any medicine to treat diarrhea without first checking with your doctor. If you have any questions or if mild diarrhea continues or gets worse, check with your doctor.

Serious side effects of dalbavancin

Along with its needed effects, dalbavancin may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking dalbavancin:

Other side effects of dalbavancin

Some side effects of dalbavancin may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

For healthcare professionals

Applies to dalbavancin: intravenous powder for injection.

General adverse events

The most common adverse reactions in adult patients were nausea, headache, and diarrhea; these were generally of mild or moderate severity.^[Ref]

Cardiovascular

• Uncommon (0.1% to 1%): Flushing, phlebitis
• Frequency not reported: Wound hemorrhage^[Ref]

Dermatologic

• Common (1% to 10%): Rash, pruritus
• Uncommon (0.1% to 1%): Urticaria
• Frequency not reported: Petechiae, skin reactions^[Ref]

Gastrointestinal

• Common (1% to 10%): Nausea, diarrhea, vomiting
• Uncommon (0.1% to 1%): Constipation, abdominal pain, dyspepsia, abdominal discomfort, Clostridioides difficile colitis, oral candidiasis
• Frequency not reported: Gastrointestinal hemorrhage, melena, hematochezia, C difficile-associated diarrhea^[Ref]

Genitourinary

• Uncommon (0.1% to 1%): Vulvovaginal mycotic infection, urinary tract infection, vulvovaginal pruritus

Hematologic

• Uncommon (0.1% to 1%): Anemia, thrombocytosis, eosinophilia, leukopenia, neutropenia, increased platelet count
• Frequency not reported: Hemorrhagic anemia, thrombocytopenia, increased INR, spontaneous hematoma

Hepatic

• Uncommon (0.1% to 1%): Increased ALT, increased AST, abnormal liver function test, increased transaminases, increased hepatic enzyme, increased GGT
• Frequency not reported: Hepatotoxicity, increased hepatic transaminases^[Ref]

Among patients with normal baseline ALT levels treated with this drug, 17 (0.8%) had post-baseline ALT elevations greater than 3 times the upper limit of normal (3 x ULN), including 5 patients with post-baseline ALT values greater than 10 x ULN; among patients with normal baseline ALT levels treated with comparators, 2 (0.2%) had post-baseline ALT elevations greater than 3 x ULN, but not greater than 10 x ULN. Of the 17 patients treated with this drug, 15 had underlying conditions that could affect liver enzymes (including chronic viral hepatitis, history of alcohol abuse, metabolic syndrome). In 1 trial, 1 patient treated with this drug had post-baseline ALT elevations greater than 20 x ULN. ALT elevations were reversible in all patients with follow-up assessments.^[Ref]

Hypersensitivity

• Rare (0.01% to 0.1%): Anaphylactoid reaction
• Frequency not reported: Serious hypersensitivity (anaphylactic)^[Ref]

Metabolic

• Uncommon (0.1% to 1%): Decreased appetite, increased blood uric acid
• Frequency not reported: Hypoglycemia^[Ref]

Nervous system

• Common (1% to 10%): Headache
• Uncommon (0.1% to 1%): Dizziness, dysgeusia^[Ref]

Other

• Uncommon (0.1% to 1%): Infusion-related reactions, fungal infection, increased blood lactate dehydrogenase, increased blood alkaline phosphatase, increased body temperature
• Frequency not reported: Pyrexia
• Postmarketing reports: Back pain (as an infusion-related reaction)

Psychiatric

• Uncommon (0.1% to 1%): Insomnia

Respiratory

• Uncommon (0.1% to 1%): Cough
• Rare (0.01% to 0.1%): Bronchospasm^[Ref]

See also:

Further information

Dalbavancin side effects can vary depending on the individual. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Note: Medication side effects may be underreported. If you are experiencing side effects that are not listed, submit a report to the FDA by following this guide.

Medical Disclaimer